iRhythm Technologies Inc. (IRTC) saw its shares plummet 5.11% during intraday trading on Friday, as the stock faced selling pressure following a series of analyst price target reductions.
Despite reporting strong quarterly earnings that significantly beat estimates, with adjusted EPS of $0.29 versus the $0.03 consensus expectation and revenue of $208.89 million exceeding the $201.59 million forecast, multiple Wall Street firms have recently lowered their price targets on the healthcare technology company.
JP Morgan reduced its target to $215 from $240, Canaccord lowered its target to $198 from $212, and Truist Securities adjusted its price target to $200 from $215, though all three firms maintained their Buy ratings on the stock. These downward revisions in price targets appear to be weighing on investor sentiment despite the company's solid financial performance.
Comments